1. Home
  2. NPCT vs RCEL Comparison

NPCT vs RCEL Comparison

Compare NPCT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Core Plus Impact Fund of Beneficial Interest

NPCT

Nuveen Core Plus Impact Fund of Beneficial Interest

HOLD

Current Price

$10.20

Market Cap

306.8M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.44

Market Cap

114.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPCT
RCEL
Founded
2020
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.8M
114.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NPCT
RCEL
Price
$10.20
$3.44
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.75
AVG Volume (30 Days)
107.1K
202.2K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
9.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$72,401,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$27.56
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.59
52 Week Low
$8.58
$3.25
52 Week High
$10.63
$14.16

Technical Indicators

Market Signals
Indicator
NPCT
RCEL
Relative Strength Index (RSI) 30.27 40.80
Support Level $10.16 $3.25
Resistance Level $10.59 $3.58
Average True Range (ATR) 0.09 0.18
MACD -0.02 0.00
Stochastic Oscillator 7.55 33.33

Price Performance

Historical Comparison
NPCT
RCEL

About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest

Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: